NCT06243510

Comparison of Apixaban Versus Enoxaparin

Comparison of Apixaban Versus Enoxaparin as Venous Thromboembolism Prophylaxis After Radical Cystectomy

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder. The main questions it aims to answer are: * Are patients equally adherent to apixaban as they are enoxaparin? Why or why not? * Do patients prefer apixaban or enoxaparin? * What is the typical patient cost to take apixaban vs enoxaparin after surgery? Participants will be randomized to receive a prescription for either enoxaparin or apixaban which they will then fill themselves and self-administer at home until post-operative day 30. They will receive phone calls from study coordinators at days 30 and 90 to complete questionaries over the phone to assess trial outcomes.

Conditions

• Bladder Cancer

Interventions

Type	Name	Description
OTHER	apixaban	Participants will be randomized to receive a prescription for prophylactic apixaban
OTHER	enoxaparin	Participants will be randomized to receive a prescription for prophylactic enoxaparin

Timeline

• Start date: 2023-11-24
• Primary completion: 2026-03-15
• Completion: 2026-06-01
• First posted: 2024-02-06
• Last updated: 2026-01-28

Locations

1 site across 1 country: United States